Nebulizer maker Aerogen and CanSino Biologics have signed a development and commercial supply deal for the use of Aerogen’s vibrating mesh nebulizer technology for delivery of CanSinoBIO’s Convidecia inhaled vaccine against COVID-19. Terms of the deal were not disclosed.
Earlier this year, CanSinoBio announced positive results from a Phase 1 trial of the Ad5-nCoV vaccine; the company now says that interim data from Phase 3 trials demonstrate an efficacy of greater than 95% against severe disease 14 days post dose. CanSinoBIO also said that it plans to submit a marketing application in China and is readying clinical trials necessary for submissions in other countries.
Aerogen CEO and founder John Power commented, “The world has an urgent need for an effective, low cost, globally scalable and globally accessible solution to mass vaccination. The pioneering development undertaken by Aerogen and CanSino has resulted in a system that meets all these requirements and with a capacity to vaccinate in the billions.”
CanSinoBIO Chairman and CEO Xuefeng Yu said, “Our partnership with Aerogen started in 2013 and for almost a decade, we’ve been advancing the possibility of aerosol drug delivery. The innovative development on the inhaled delivery of COVID-19 vaccine is the testimony of our collaborative efforts. It is demonstrated that the aerosolized vaccine can stimulate mucosal immunity and significantly reduce the risk of transmission, which could be a solution to rapidly build mass immune protection and accelerate the end of the pandemic.”
Read the Aerogen and CanSinoBio press release.
